BiOasis announced siRNA breakthrough; Mystic Pharma receives patent for powdered formulation;

> Mystic Pharma received a patent Notice of Allowance for their powdered formulations of drugs patients can self-administer. Release

> A new cancer therapy research partnership has been arranged between Molecular Targeting Technologies (MTTI) and Taiwan's National Health Research Institutes (NHRI). Release

> Florida Agricultural and Mechanical University received a $100,000 grant from the National Science Foundation to use toward a pilot program launch with the National High Magnetic Field Laboratory. If the program is a success, it can lead to additional millions in funding. Release

> Up and coming biopharma, biOasis announced that it discovered a carrier peptide, Transcendpep, that can cross the blood-brain barrier, effectively delivering siRNA's to the brain. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.